BioRestorative Therapies IncNASDAQ:BRTX
- LAST PRICE1.4450
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.3600/ 22
- Ask / Lots1.5000/ 2
- Open / Previous Close--- / 1.4450
- Day Range---
- 52 Week Range
- Volume2,375
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BRTX |
|---|---|---|
| 09:35 ET | 435 | 1.4536 |
| 09:42 ET | 1000 | 1.4119 |
| 09:44 ET | 335 | 1.47 |
| 09:57 ET | 1000 | 1.4408 |
| 10:02 ET | 3035 | 1.4 |
| 10:09 ET | 1400 | 1.43 |
| 10:11 ET | 500 | 1.45 |
| 10:18 ET | 300 | 1.38 |
| 10:24 ET | 300 | 1.3816 |
| 10:33 ET | 200 | 1.38 |
| 10:45 ET | 460 | 1.36 |
| 10:56 ET | 700 | 1.32 |
| 11:07 ET | 100 | 1.37 |
| 11:18 ET | 1300 | 1.33 |
| 11:25 ET | 175 | 1.41 |
| 12:21 ET | 1100 | 1.3899 |
| 12:42 ET | 369 | 1.3799 |
| 12:53 ET | 197 | 1.38 |
| 12:55 ET | 100 | 1.38 |
| 01:02 ET | 600 | 1.3957 |
| 01:04 ET | 7597 | 1.385 |
| 01:08 ET | 3003 | 1.4 |
| 01:13 ET | 9801 | 1.4 |
| 01:24 ET | 1200 | 1.405 |
| 01:31 ET | 1220 | 1.405 |
| 01:33 ET | 1297 | 1.4114 |
| 02:00 ET | 103 | 1.38 |
| 02:39 ET | 300 | 1.4043 |
| 03:10 ET | 100 | 1.4138 |
| 03:30 ET | 100 | 1.4 |
| 03:50 ET | 150 | 1.445 |
Nov 13, 2024
BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data, from 7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 12, 2024
*DJ BioRestorative Therapies 3Q Loss/Shr 13c >BRTX, from 4:47PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:47PM ET on Tuesday Nov 12, 2024 by Dow Jones*DJ BioRestorative Therapies 3Q Loss/Shr 13c >BRTX, from 4:20PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:20PM ET on Tuesday Nov 12, 2024 by Dow JonesBioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 6, 2024
BioRestorative Therapies to Present New Clinical Data at the ORS PSRS 7th International Spine Research Symposium, from 7:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
7:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioRestorative Therapies Inc | 10.0M | -2.0x | --- |
Oncotelic Therapeutics Inc | 10.3M | -2.2x | --- |
Imunon Inc | 10.0M | -0.4x | --- |
Kiora Pharmaceuticals Inc | 9.9M | -5.5x | --- |
Onconetix Inc | 9.4M | 0.0x | --- |
CeCors Inc | 10.5M | --- | --- |
Company Information
BioRestorative Therapies, Inc. is engaged in developing therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). The Company has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs.
Contact Information
- Headquarters
- 40 MARCUS DRIVEMELVILLE, NY, United States 11747
- Phone
- 631-760-8100
- Fax
- ---
Executives
- Chairman of the Board, President, Chief Executive Officer
- Lance Alstodt
- Chief Financial Officer
- Robert Kristal
- Vice President - Quality Assurance/Regulatory Compliance
- Robert Paccasassi
- Vice President - Research & Development, Secretary, Director
- Francisco Silva
- Independent Director
- Nickolay Kukekov
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $10.0M |
|---|---|
Revenue (TTM) | $377.0K |
Shares Outstanding | 6.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.71 |
Book Value | $2.13 |
P/E Ratio | -2.0x |
Price/Sales (TTM) | 26.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,205.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
